Mattel slips after analyst notes ‘growing’ and ‘immediate’ capital needs
Shares of Mattel (MAT) slipped in afternoon trading after an analyst from Jefferies said the toy maker's capital needs are "immediate" and "growing." Separately, an...
Author : The Fly
Airbus expects A320neo deliveries ‘slightly below target’
Airbus comments, "The industrial ramp up on the A350 continues to make good progress, with the programme well on track to meet the monthly production...
Tesla will likely miss Q3 estimates, but don’t get ‘spooked,’ says Nomura
Nomura Instinet analyst Romit Shah attributes the recent 10% pullback in shares of Tesla to Model 3 production, workforce restructuring and autonomous concerns as well...
Piper boosts Apple price target to $200 after iPhone survey
Piper Jaffray analyst Michael Olson raised his price target for Apple shares to $200 from $196 after surveying 300 iPhone owners. Apple closed yesterday up...
Braskem in early takeover talks with LyondellBasell, WSJ reports
LyondellBasell (LYB) has made a takeover approach to Braskem (BAK) and the talks are at an early stage, Dana Mattioli and Dana Cimilluca of Wall...
On The Fly: What to watch in Under Armour earnings report
Under Armour (UA, UAA) is scheduled to report results of its third fiscal quarter before the market open on Tuesday, October 31, with a conference...
On The Fly: Top stock stories at midday
The S&P opened in negative territory as the week began with the Justice Department indictment of former Trump campaign chairman Paul Manafort. The weakness in...
Oppenheimer raises Celgene target to $168 on ‘highly positive’ study
Oppenheimer analyst Leah Rush Cann raised her price 12- to 18-month price target for shares of Celgene (CELG) to $168 from $163 citing the "highly...
Care.com slides after after unknown short seller attacks on Twitter
Shares of Care.com (CRCM), the operator of an online marketplace for finding and managing family care, are sliding after short seller "Batman Research" published a...
Bristol-Myers rises after Merck pulls cancer drug combo filing in Europe
Shares of Bristol-Myers Squibb (BMY) are on the rise after competitor Merck (MRK) announced it is withdrawing its European application for a combination regimen featuring...